Illumina secures FDA approval for comprehensive cancer test and two companion diagnostics
Illumina, Inc. (NASDAQ: ILMN), a global leader in the field of DNA sequencing and array-based technologies, has secured crucial approval from the Food and Drug ... Read More
Lilly’s Retevmo outperforms in trials for RET fusion-positive NSCLC and RET-mutant MTC
Eli Lilly (Lilly) has disclosed the results from two pivotal Phase 3 studies, LIBRETTO-431 and LIBRETTO-531, evaluating the efficacy of Retevmo in treating patients with ... Read More